Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133843 | 0.87 | MAOB (0.59) | MAOBMAOA | |
| SCHEMBL2131850 | 0.85 | KDM4E (0.55) | MAOBMAOACHEK2 | |
| SCHEMBL2132151 | 0.82 | MAOB (0.58) | MAOBMAOA | |
| SCHEMBL12832428 | 0.80 | HRH4 (0.47) | CHEK2 | |
| SCHEMBL3064556 | 0.77 | CHEK2 (0.50) | CHEK2 | |
| SCHEMBL2133081 | 0.76 | MAOB (0.49) | MAOBPPARAMAOA | |
| SCHEMBL4466653 | 0.75 | ALDH1A1 (0.61) | MAOBMAOACHEK2 | |
| SCHEMBL2129893 | 0.74 | MAOB (0.47) | MAOB | |
| SCHEMBL2132114 | 0.74 | FFAR1 (0.45) | MAOBMAOACHEK2 | |
| SCHEMBL2134219 | 0.73 | MAOB (0.48) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350039-B2 | Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-08 | — | — | US | claimed |
| US-8350039-B2 | Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120101125-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101125-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | MAOB 475/4885S1PR1 4332/4885PPARD 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.